Answers are grounded in this paper and cite their sources.
Demonstrates enhanced nasal permeation and cytotoxicity against neuroblastoma with optimized niosomes, suggesting a promising therapeutic approach.
Aims To develop and evaluate a Quality-by-Design (QbD) optimized curcumin-loaded niosomal (OptCUR-NS) formulation for intranasal delivery and determine its delivery performance and in vitro activity against neuroblastoma.Materials and methods A D-optimal design was used to optimize the Span 60:cholesterol ratio, Span 60:dicetyl phosphate ratio, and curcumin concentration. OptCUR-NS was characterized for vesicle properties, solid-state behavior, release, ex vivo nasal permeation, endothelial transport, cytotoxicity in SK-N-SH and SH-SY5Y cells, cellular uptake, cell-cycle distribution, migration, and cytocompatibility in F-180 fibroblasts.Results OptCUR-NS showed a particle size of 133.57 nm, surface charge of −48.16 mV, and entrapment efficiency of 62.05%. It exhibited biphasic release and increased nasal flux by 56% relative to free curcumin. Endothelial transport increased 1.57-fold without a significant change in transendothelial electrical resistance. In SK-N-SH cells, IC50 decreased from 78.94 to 69.67 µM at 24 h and from 70.54 to 50.24 µM at 48 h. Similar enhancement was observed in SH-SY5Y cells. Uptake was predominantly clathrin-dependent, accompanied by S-phase accumulation and reduced cell migration.Conclusions OptCUR-NS improved curcumin permeation, endothelial transport, cellular uptake, and in vitro anti-neuroblastoma activity while maintaining fibroblast cytocompatibility and endothelial monolayer integrity under the conditions tested.
No takes yet. Share an insight, caveat, or question.
Jayoush et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: